Top Markets
Coin of the day
TaiGen Biopharmaceuticals Holdings Limited TaiGen Biopharmaceuticals Holdings Limited

TaiGen Biopharmaceuticals Holdings Limited

4157
株式のランク #18388
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm... TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
株価
$0.28078542
時価総額
$199.87M
変化(1日)
-0.34%
変化(1年)
-10.19%
TW
取引 TaiGen Biopharmaceuticals Holdings Limited (4157)

カテゴリー

TaiGen Biopharmaceuticals Holdings Limited(4157)のP/B比率
2026 時点のP/B比率 TTM: 0
TaiGen Biopharmaceuticals Holdings Limited の最新の財務報告および株価によると、現在のP/B比率(TTM)は 0 です。2026 年末時点でのP/B比率は 0 でした。
TaiGen Biopharmaceuticals Holdings Limited の P/B 比率の履歴(2026 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.828 -
US
7.5116 -
NL
8.2199 -
US
3.9942 -
AU
- -
CH